Summary of use during lactation
Voxelotor is an orally administered drug that binds to hemoglobin S, inhibiting polymerization. No information is available on the appearance of voxelotor in milk or on the safety of the drug in breastfed infants, but its low molecular weight of 337 Da indicates that it probably passes into milk. Because of the potential for serious adverse reactions in the infant, breastfeeding is currently not recommended during treatment and for at least 2 weeks after the last dose.
Drug levels in milk and infant serum
Maternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Relevant published information was not found as of the revision date.
Effects in breastfed infants
Relevant published information was not found as of the revision date.
Effects on lactation and breastmilk
Relevant published information was not found as of the revision date.
Source: Drugs and Lactation Database (LactMed®), National Institute of Child Health and Human Development, NCBI Bookshelf. Check LactMed for the most recent revision.
Medical disclaimer: This page is for qualified healthcare professionals and is a decision-support aid only. It does not replace clinical judgement, local protocols or product information. Verify every dose and threshold before use. See the full Medical Disclaimer.